A sugar molecule known as a glycan could play a key role in the development of Alzheimer’s disease, according to a new study.
For the study, researchers conducted a bit of “reverse engineering,” using brain tissues from five people who died with Alzheimer’s disease.
If further research confirms the glycan finding, the molecule could serve as a target for early diagnostic tests, treatments, and perhaps prevention of Alzheimer’s disease, say the researchers.
Alzheimer’s disease is the most common form of dementia in the United States. Affecting an estimated 5.8 million Americans, the progressive disorder occurs when nerve cells in the brain die due to the buildup of harmful forms of proteins called amyloid and tau.
Cleaning up the disease-causing forms of amyloid and tau is the job of the brain’s immune cells, called microglia. Earlier studies found that when cleanup is impaired, Alzheimer’s disease is more likely to occur. In some people, this is caused by an overabundance of a receptor on the microglia cells, called CD33.
“Receptors are not active on their own. Something needs to connect with them to block microglia from cleaning up these toxic proteins in the brain,” says Ronald Schnaar, professor of pharmacology at the Johns Hopkins University School of Medicine and director of the laboratory that led the study.
Alzheimer’s sugar building blocks
Past studies from the researchers showed that for CD33, these “connector” molecules are special sugars. Known to scientists as glycans, these molecules are ferried around the cell by specialized proteins that help them find their appropriate receptors. The protein-glycan combination is called a glycoprotein.
In a bid to find out which specific glycoprotein connects with CD33, Schnaar’s research team obtained brain tissue from five people who died of Alzheimer’s disease and from five people who died from other causes from the Johns Hopkins Alzheimer’s Disease Research Center. Among the many thousands of glycoproteins they gathered from the brain tissues, only one connected to CD33.
To identify this mystery glycoprotein, the researchers first needed to separate it from the other brain glycoproteins. Since it was the only one in the brain that attached itself to CD33, they used this feature to “catch” it and separate it.
Glycans are made up of various sugar building blocks that influence the molecule’s interactions. Such sugars can be identified by their component parts. The researchers used chemical tools to deconstruct the glycan step by step, laying out the identity and order of its building blocks. The researchers identified the glycan portion of the glycoprotein as sialylated keratan sulfate.
Then, the researchers determined the protein component’s identity by taking its “fingerprint” using mass spectroscopy, which identifies protein building blocks. By comparing the molecular makeup of the protein with a database of known protein structures, the research team was able to conclude the protein portion of the glycoprotein was receptor tyrosine phosphatase (RPTP) zeta. The researchers named the combined glycoprotein structure RPTP zeta S3L.
The group had previously found the same glycan “signature” on a protein that controls allergic responses in the airway, and that disrupting the glycan dampened allergic responses in mice.
“We suspect the glycan signature carried on RPTP zeta may have a similar role in deactivating microglia through CD33,” says Anabel Gonzalez-Gil Alvarenga, postdoctoral fellow in the Schnaar laboratory and first author of the study in the Journal of Biological Chemistry.
New drug targets for Alzheimer’s
Further experiments showed that the brain tissue of the five people who died with Alzheimer’s disease had more than twice as much RPTP zeta S3L as the donors who did not have the disease. This implies that this glycoprotein may be connecting with more CD33 receptors than a healthy brain, limiting the brain’s ability to clean up harmful proteins.
“Identifying this unique glycoprotein provides a step toward finding new drug targets and potentially early diagnostics for Alzheimer’s disease,” says Gonzalez-Gil.
Next, the researchers plan to further study RPTP zeta S3L’s structure to determine how its attached glycans give the glycoprotein its unique ability to interact with CD33.
Additional coauthors are from the University of Georgia, the State University of New York Upstate Medical University, and Johns Hopkins.
The National Institute on Aging; the National Heart, Lung, and Blood Institute; and the National Institute of General Medical Sciences funded the work. The Johns Hopkins Alzheimer’s Disease Research Center provided the human brain tissues.
Source: Johns Hopkins University
